{"success":true,"data":{"pressRelease":{"id":"141348","rtpr_id":"nBw3YS2BLa-20260911","ticker":"ABLD","exchange":"Euronext Paris","all_tickers":["ABLD"],"title":"ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen","author":"Business Wire","published_at":"2026-09-11T10:01:00.147Z","article_body":"ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen\n\nRegulatory News:\n\nABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the \"Company\"),\na company specialized in molecular diagnostics solutions, healthcare software\nand services supporting clinical research, today announced that it has filed,\non Friday, September 11, 2026, a bid to acquire the business operations and\nassets of IntegraGen, a company specializing in genomic analysis of nucleic\nacids, particularly in oncology and rare genetic diseases, currently subject\nto judicial reorganization proceedings before the Commercial Court of Évry.\n\nThis initiative is consistent with ABL Diagnostics’ growth strategy and its\nongoing evaluation of external growth opportunities complementary to its\ncurrent portfolio.\n\nThe proposed acquisition, filed pursuant to Article L.642-1 of the French\nCommercial Code, remains subject to the decision of the Commercial Court of\nÉvry. At this stage, there can be no assurance that ABL Diagnostics will be\nselected as the successful bidder.\n\nThe Company will keep the market informed of any material developments\nregarding this matter in accordance with applicable regulatory requirements.\n\nRegulatory Information\n\nThis press release contains inside information within the meaning of Article 7\nof Regulation (EU) No. 596/2014 on market abuse (\"MAR\"). Its disclosure is\nmade in accordance with Article 17 of MAR. Forward-looking statements\ncontained herein are inherently subject to risks and uncertainties, including\nthose related to the outcome of judicial proceedings and the approval of third\nparties.\n\nAbout ABL Diagnostics (ABLD)\n\nABL Diagnostics (ABLD) is an international company that specializes in\ninnovative molecular biology tests and global solutions for its customers:\n\n\n * Molecular polymerase chain reaction (PCR) detection – UltraGene, and\n\n * Genotyping by DNA sequencing – DeepChek®.\n\nABL Diagnostics markets its entire product range globally through its own\nsales team and a network of exclusive distributors active on all continents.\nABL Diagnostics' customers are academic clinical pathology laboratories,\nprivate reference laboratories and researchers willing to implement innovative\nand robust microbiological content in constant expansion.\n\nFollowing the acquisition of TEXCELL’s operations, ABL Diagnostics is\nexpanding its activities in the life sciences sector by integrating expertise\nand services dedicated to virology, biosafety testing and biopharmaceutical\ndevelopment support.\n\nABL Diagnostics has been marketing the products and services of its sister\ncompany CDL Pharma since the second half of 2025 through an intra-group\nstrategy agreement.\n\nAn expanding portfolio of microbiology products:\n\n\n * HIV – Drug resistance testing, including a whole genome kit.\n\n * SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.\n\n * Microbiome and taxonomy – 16s/18s RNA-based analyses.\n\n * Other viral and bacterial targets – Comprehensive molecular assays.\n\nIntegrated Solutions\n\n\n * Real-time syndromic PCR tests\n\n * Nadis® – Patient Medical Record used in more than 200 hospitals in France\nfor the management of HIV and hepatitis.\n\nABL Diagnostics, headquartered in Woippy, is a public limited company listed\non compartment B of the regulated market of Euronext in Paris (Euronext: ABLD\n– ISIN: FR001400AHX6). These molecular biology products generate recurring\nrevenues and cover one of the largest portfolios of applications in\nmicrobiology.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260911655644/en/\n(https://www.businesswire.com/news/home/20260911655644/en/)\n\nABL Diagnostics SA \n\nSociété anonyme au capital de 1 611 465,60 euros\n\nHeadquarters : 72C route de Thionville - 57140 WOIPPY\n\n552 064 933 R.C.S. METZ\n\nTel : +33 (0)7 83 64 68 50\n\nEmail : info@abldiagnostics.com \n(mailto:info@abldiagnostics.com) \nhttps://www.abldiagnostics.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.abldiagnostics.com%2F&esheet=54602036&newsitemid=20260911655644&lan=en-US&anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&index=1&md5=1778177a53971b0a44bb53ba19f1a84d)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw3YS2BLa-20260911","title":"ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen","author":"Business Wire","ticker":"ABLD","created":"2026-09-11T10:01:00.147Z","tickers":["ABLD"],"exchange":"Euronext Paris","article_body":"ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen\n\nRegulatory News:\n\nABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the \"Company\"),\na company specialized in molecular diagnostics solutions, healthcare software\nand services supporting clinical research, today announced that it has filed,\non Friday, September 11, 2026, a bid to acquire the business operations and\nassets of IntegraGen, a company specializing in genomic analysis of nucleic\nacids, particularly in oncology and rare genetic diseases, currently subject\nto judicial reorganization proceedings before the Commercial Court of Évry.\n\nThis initiative is consistent with ABL Diagnostics’ growth strategy and its\nongoing evaluation of external growth opportunities complementary to its\ncurrent portfolio.\n\nThe proposed acquisition, filed pursuant to Article L.642-1 of the French\nCommercial Code, remains subject to the decision of the Commercial Court of\nÉvry. At this stage, there can be no assurance that ABL Diagnostics will be\nselected as the successful bidder.\n\nThe Company will keep the market informed of any material developments\nregarding this matter in accordance with applicable regulatory requirements.\n\nRegulatory Information\n\nThis press release contains inside information within the meaning of Article 7\nof Regulation (EU) No. 596/2014 on market abuse (\"MAR\"). Its disclosure is\nmade in accordance with Article 17 of MAR. Forward-looking statements\ncontained herein are inherently subject to risks and uncertainties, including\nthose related to the outcome of judicial proceedings and the approval of third\nparties.\n\nAbout ABL Diagnostics (ABLD)\n\nABL Diagnostics (ABLD) is an international company that specializes in\ninnovative molecular biology tests and global solutions for its customers:\n\n\n * Molecular polymerase chain reaction (PCR) detection – UltraGene, and\n\n * Genotyping by DNA sequencing – DeepChek®.\n\nABL Diagnostics markets its entire product range globally through its own\nsales team and a network of exclusive distributors active on all continents.\nABL Diagnostics' customers are academic clinical pathology laboratories,\nprivate reference laboratories and researchers willing to implement innovative\nand robust microbiological content in constant expansion.\n\nFollowing the acquisition of TEXCELL’s operations, ABL Diagnostics is\nexpanding its activities in the life sciences sector by integrating expertise\nand services dedicated to virology, biosafety testing and biopharmaceutical\ndevelopment support.\n\nABL Diagnostics has been marketing the products and services of its sister\ncompany CDL Pharma since the second half of 2025 through an intra-group\nstrategy agreement.\n\nAn expanding portfolio of microbiology products:\n\n\n * HIV – Drug resistance testing, including a whole genome kit.\n\n * SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.\n\n * Microbiome and taxonomy – 16s/18s RNA-based analyses.\n\n * Other viral and bacterial targets – Comprehensive molecular assays.\n\nIntegrated Solutions\n\n\n * Real-time syndromic PCR tests\n\n * Nadis® – Patient Medical Record used in more than 200 hospitals in France\nfor the management of HIV and hepatitis.\n\nABL Diagnostics, headquartered in Woippy, is a public limited company listed\non compartment B of the regulated market of Euronext in Paris (Euronext: ABLD\n– ISIN: FR001400AHX6). These molecular biology products generate recurring\nrevenues and cover one of the largest portfolios of applications in\nmicrobiology.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260911655644/en/\n(https://www.businesswire.com/news/home/20260911655644/en/)\n\nABL Diagnostics SA \n\nSociété anonyme au capital de 1 611 465,60 euros\n\nHeadquarters : 72C route de Thionville - 57140 WOIPPY\n\n552 064 933 R.C.S. METZ\n\nTel : +33 (0)7 83 64 68 50\n\nEmail : info@abldiagnostics.com \n(mailto:info@abldiagnostics.com) \nhttps://www.abldiagnostics.com/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.abldiagnostics.com%2F&esheet=54602036&newsitemid=20260911655644&lan=en-US&anchor=https%3A%2F%2Fwww.abldiagnostics.com%2F&index=1&md5=1778177a53971b0a44bb53ba19f1a84d)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-11T10:01:00.188162874Z","server_sent_at_ms":1789120860188},"received_at":"2026-09-11T10:01:00.242Z","source_url":"https://www.businesswire.com/news/home/20260911655644/en/"},"analysis":{"id":"130184","press_release_id":"141348","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["bid outcome is contingent on the Commercial Court of Évry with no assurance ABL will be selected as successful bidder","target IntegraGen is in judicial reorganization (distressed asset), carrying integration and liability risk","no deal value, consideration structure, or financing details disclosed"],"eventType":"m_and_a","narrative":"ABL Diagnostics filed a bid on September 11, 2026 to acquire the business operations and assets of IntegraGen, a genomics company currently in judicial reorganization before the Commercial Court of Évry.\n\nThe bid was filed under Article L.642-1 of the French Commercial Code, and the company explicitly cautioned there is no assurance it will be selected as the successful bidder.\n\nIntegraGen specializes in genomic analysis of nucleic acids in oncology and rare genetic diseases, which ABL describes as complementary to its molecular diagnostics, healthcare software, and clinical research services portfolio.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Opportunistic distressed-asset bid: ABL moves on IntegraGen's oncology/rare-disease genomics assets out of receivership, but the deal lives or dies with the Évry court."},"keyFigures":{},"quotedText":"This initiative is consistent with ABL Diagnostics’ growth strategy and its ongoing evaluation of external growth opportunities complementary to its current portfolio.","namedEntities":{"people":[],"products":["UltraGene","DeepChek®","Nadis®"],"companies":[{"name":"ABL Diagnostics","ticker":"ABLD","relationship":"filer / bidder"},{"name":"IntegraGen","relationship":"target (in judicial reorganization before the Commercial Court of Évry)"},{"name":"TEXCELL","relationship":"prior acquisition referenced in company boilerplate"},{"name":"CDL Pharma","relationship":"sister company whose products ABL markets under an intra-group agreement"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"A filed takeover bid for a distressed target's operations is a material strategic move for a small-cap diagnostics company, but no deal value or financing terms were disclosed and success is contingent on the Commercial Court of Évry selecting ABL as the winning bidder."},"tickerRelevance":{"others":[],"primary":"ABLD"},"globalImportance":28,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"certainty":"contingent-on-court-decision","tickerTier":"small-cap","eventGravity":"takeover-bid-filed-for-distressed-target","sectorWeight":"health-care-diagnostics","dealValueDisclosed":false,"householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"ABL Diagnostics filed a bid on September 11, 2026 to acquire the business operations and assets of IntegraGen, a genomics company currently in judicial reorganization before the Commercial Court of Évry.\n\nThe bid was filed under Article L.642-1 of the French Commercial Code, and the company explicitly cautioned there is no assurance it will be selected as the successful bidder.\n\nIntegraGen specializes in genomic analysis of nucleic acids in oncology and rare genetic diseases, which ABL describes as complementary to its molecular diagnostics, healthcare software, and clinical research services portfolio.","key_figures":{},"named_entities":{"people":[],"products":["UltraGene","DeepChek®","Nadis®"],"companies":[{"name":"ABL Diagnostics","ticker":"ABLD","relationship":"filer / bidder"},{"name":"IntegraGen","relationship":"target (in judicial reorganization before the Commercial Court of Évry)"},{"name":"TEXCELL","relationship":"prior acquisition referenced in company boilerplate"},{"name":"CDL Pharma","relationship":"sister company whose products ABL markets under an intra-group agreement"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-11T10:01:37.138Z","global_importance":28,"audience_relevance":15,"importance_components":{"certainty":"contingent-on-court-decision","tickerTier":"small-cap","eventGravity":"takeover-bid-filed-for-distressed-target","sectorWeight":"health-care-diagnostics","dealValueDisclosed":false,"householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":null,"modelName":"glm-5.3-flash"}}